Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort

Int J Infect Dis. 2022 Jul:120:187-195. doi: 10.1016/j.ijid.2022.04.019. Epub 2022 Apr 14.

Abstract

Objectives: Besides SARS-CoV-2-directed humoral immune responses, T cell responses are indispensable for effective antiviral immunity. Recent data have shown a correlation between COVID-19 symptoms and humoral immune response, but so far, little is known about the association of SARS-CoV-2-directed T cell responses and disease severity. Herein, we evaluated the prevalence of different clinical COVID-19 symptoms in relation to SARS-CoV-2-directed humoral and cellular immune responses.

Methods: The severity of eight different symptoms during acute infection were assessed using questionnaires from 193 convalescent individuals and were evaluated in relation to SARS-CoV-2 antibody levels and intensity of SARS-CoV-2-specific T cell responses 2-8 weeks after positive polymerase chain reaction.

Results: Although increased IgG serum levels could be associated with severity of most symptoms, no difference in T cell response intensity between different symptom severities was observed for the majority of COVID-19 symptoms. However, when analyzing loss of smell or taste and cough, awareness of more severe symptoms was associated with reduced T cell response intensities.

Conclusions: These data suggest that rapid virus clearance mediated by SARS-CoV-2-specific T cells prevents severe symptoms of COVID-19.

Keywords: SARS-CoV-2; T cells; antibody; immune response; symptoms.

MeSH terms

  • Antibodies, Viral
  • COVID-19*
  • Humans
  • Immunity, Cellular
  • Immunity, Humoral
  • Infections*
  • Prevalence
  • SARS-CoV-2

Substances

  • Antibodies, Viral